Caroline Loew

Join us at the TD Cowen Health Care Conference, where Mural CEO Caroline Loew will share how we're leveraging our novel protein engineering to advance cytokine-based immunotherapies. Register for the webcast: bit.ly/4b8oIHx $MURA

Today, we announced our financial results for the third quarter of 2024. Read the announcement for updates and progress made across our pipeline as we work to address key limitations with cytokine therapies to unleash their full potential: bit.ly/4esaP7a $MURA

We're thrilled to welcome Sachiyo Minegishi to our board of directors! With over two decades of industry experience, we look forward to leveraging Sachiyo's expertise in navigating important clinical, financial, & corporate milestones. Read more: bit.ly/4eyEzQs #biotech

We're looking forward to hosting our first virtual investor day on September 26. Hear from Mural leadership and clinicians about our pipeline and potential of cytokine-based immunotherapies. Read to learn more: bit.ly/4gmrKui #biotechnology $MURA

.@BioPharmaDive's @ByJonGardner marks the 10th anniversary of the first PD-1 inhibitor approved for melanoma in a special report. Read about the progress made a decade ago & hear from pioneers like Mural CEO Caroline Loew on where we are today: bit.ly/4dRPWmo #oncology

We're looking forward to participating in the upcoming @MorganStanley and @HCWCO investor conferences in September. Learn more about our presentations: bit.ly/4fZcD9H #investors $MURA

Today, $MURA announced financial results for the second quarter of 2024 and provided a business update. Read the release to see our recent corporate highlights and upcoming milestones across our pipeline: bit.ly/3WQIwc2 #biotechnology

We're thrilled to welcome George Golumbeski to our board of directors! Dr. Golumbeski has extensive BD experience, and we look forward to his expertise as we continue to advance our pipeline. Read about the appointment: bit.ly/3Yqz9SL #biotechnology

Did you catch our poster presentation at the @ASCO annual meeting? See the data that were presented on our lead candidate, nemvaleukin alfa, and view all of our recent publications: bit.ly/3KrYlzM #biotechnology #drugdevelopment #ASCO24 #innovation

Did you know that cutaneous melanoma is the most aggressive form of melanoma? Learn more about the cancer, including the signs and symptoms, or ABCDE’s: bit.ly/4ajYFuV #MelanomaAwarenessMonth24

We’re looking forward to the @ASCO annual meeting. Sarina Piha-Paul will give a poster presentation on the ARTISTRY-3 clinical trial evaluating the effects of less frequent IV dosing of our lead candidate, nemvaleukin alfa. bit.ly/4brUK0A #ASCO24 #interleukin2

What is mucosal melanoma? In recognition of #MelanomaAwarenessMonth, visit @CureMelanoma to learn more about the signs and symptoms of this rare form of melanoma: bit.ly/3UTAyik #MelanomaAwarenessMonth224

Today, we announced financial results for the first quarter of 2024 and provided a business update. Learn more about our recent corporate highlights and upcoming milestones: bit.ly/3K295F0 #biotechnology #healthcare

Check out the latest article from @Labiotech_eu, where Mural CEO Caroline Loew shares how our novel protein engineering approach may be able to harness native IL-2’s potency while overcoming the challenges historically seen with IL-2 therapies. Read the article below⬇️

We're looking forward to joining the scientific community at the @ASCO annual meeting to present clinical data on our lead candidate, nemvaleukin alpha. Learn more: bit.ly/3U6pVqI #ASCO24

Mural Oncology’s Joshua Heiber & Mark Whitmore presented at the @AACR Annual Meeting this month. Read their takeaways & learn more about the pre-clinical data from our interleukin-18 (IL-18) and IL-12 programs that were shared for the first time: bit.ly/4daBbLF #AACR24

Mural CEO Caroline Loew sat down with Jessica Merrill from Scrip to discuss our focus on building out business operations, executing our ongoing clinical trials, and creating a new culture. Scrip subscribers can read the full article here: bit.ly/3Q3xrlb

What factors does Mural CEO Caroline Loew find critical to the success of any biopharma company? In Life Science Leader, Caroline shares her perspective on the challenges & opportunities in delivering the next evolution in cancer treatment: bit.ly/4cOIusf

We were thrilled to present for the first time, preclinical data from our interleukin-18 (IL-18) and IL-12 programs at the 2024 @AACR annual meeting. Learn more about the data and see the posters we presented: bit.ly/4atuTVI #AACR24

Attending the @AACR 2024 Annual Meeting? Join us to see us present our first preclinical data from our IL-12 and IL-18 programs. Learn about the presentations: bit.ly/4c25OSQ #AACR24